DexCom, Abbott Settle
The Wall Street Journal|December 26, 2024
DexCom and Abbott Diabetes Care entered a settlement and patent cross-license agreement, resolving all outstanding litigation between the two.
CONNOR HART
DexCom, Abbott Settle

This story is from the December 26, 2024 edition of The Wall Street Journal.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the December 26, 2024 edition of The Wall Street Journal.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.